Who’s Going to TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
96 organizations and 92 speakers at the Targeted Protein Degradation (TPD) & Induced Proximity Summit 2026, a ~300-person, almost entirely industry meeting of targeted protein degradation scientists and biotech executives. As of Oct 20, 2026.
| Organization | TPD Summit 2026 Attendance |
|---|---|
Nurix Therapeutics San Francisco, CA | ◇Industry Partner |
Clinical-stage biotech developing targeted protein degraders, including BTK degraders, for cancer and inflammatory diseases. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Tue Oct 27 12:30pm Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 9:00am Session Details to be Announced AI & computational design |
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company with medicines in oncology, inflammation, cardiovascular and bone disease, and induced proximity research. | Chair Wed Oct 28 8:20am Chair’s Opening Remarks Investment, partnering & strategy Talk Wed Oct 28 9:30am Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity? Induced proximity beyond degradation Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 2:15pm GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening Screening, assays & proteomics |
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets medicines. | Talk Tue Oct 27 12:30pm Talk Thu Oct 29 9:30am Optimizing the Next Generation Degraders with Better Informatics, Descriptors & Predictive Modeling AI & computational design Panel Thu Oct 29 10:00am |
Combines proteomics and AI to discover drug targets, biomarkers and degraders. | Panel Tue Oct 27 3:10pm Talk Wed Oct 28 11:30am Proteomics & AI Platform Maps Degrader-Induced Ternary Complex Diversity to Enable Rational Degrader Design AI & computational designScreening, assays & proteomics Panel Thu Oct 29 10:00am |
Astellas Tokyo, Japan | ◇Industry Partner |
Japanese pharmaceutical company with a targeted protein degradation program, including the KRAS G12D degrader setidegrasib. | Talk Tue Oct 27 2:00pm Talk Wed Oct 28 3:00pm |
Arvinas New Haven, CT | |
Biotech developing PROTAC protein degraders for cancer and neurological diseases. | Talk Tue Oct 27 8:30am Degradation Delivered – What the First TPD Approval Means for the Future of the Field Translational & clinical developmentInvestment, partnering & strategy |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases. | Talk Wed Oct 28 2:30pm Linking Molecular Glue Binding Kinetics to Functional Performance Through Quantitative Modeling AI & computational design Talk Thu Oct 29 9:30am Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs) Degrader conjugates & tissue targeting |
Foghorn Therapeutics Cambridge, MA | |
Clinical-stage biotech targeting the chromatin regulatory system with small molecules and protein degraders for cancer. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 10:30am Proximity by Design: Harnessing Induced Proximity for Challenging Targets Degrader discovery & design |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company developing and marketing medicines in oncology, immunology, cardiovascular disease and neuroscience. | Talk Tue Oct 27 5:00pm Modelling Targeted Protein Degradation from Cells to the Clinic AI & computational design Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Yale University New Haven, CT | |
Private research university in New Haven, Connecticut, with a school of medicine. | Talk Mon Oct 26 1:45pm Enhancing Inhibition via Chemically Induced Proximity: A RIPTAC Targeting BCL6 & BET Proteins Induced proximity beyond degradation Panel Mon Oct 26 2:15pm |
C4 Therapeutics Watertown, MA | |
Clinical-stage biotech developing small-molecule targeted protein degraders for cancer. | Chair Tue Oct 27 8:20am Chair’s Opening Remarks Investment, partnering & strategy Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 11:45am |
Develops cancer therapeutics built on p27 biology, including molecular glue stabilizers, for drug-resistant cancers. | Panel Tue Oct 27 3:10pm Talk Thu Oct 29 12:15pm Locktacs for Intrinsically Disordered Proteins: First-in-Class p27 Molecular Glue Stabilizers Induced proximity beyond degradation |
Instantly find 20 buyers from companies at TPD Summit 2026
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
When and where is TPD Summit 2026?
9th TPD & Induced Proximity Summit runs October 26–29, 2026, at the Omni Boston Hotel at the Seaport in Boston, MA.
Where is the TPD Summit 2026 program?
This guide lists every organization on the TPD Summit 2026 program with its sessions; the full program is on the official website.
How do I register for TPD Summit 2026?
Fees and registration are on the organizer's registration page.
What conference is this?
The TPD & Induced Proximity Summit is an annual meeting on targeted protein degradation and induced proximity, held for the ninth time October 26–29, 2026 at the Omni Boston Hotel at the Seaport. It brings degrader and molecular glue developers in pharma and biotech together with the CROs, assay and tool companies that serve them: a Research Breakthroughs Day, two Pipeline Progression days in three tracks (Discovery, Pre-Clinical Development, Translational & Clinical Development) and a Future Technologies & Innovations Day.
What is in this guide?
Every organization we can place at TPD Summit 2026: 92 speakers from the public agenda (91 talks, panels and chaired sessions) rolled up to their companies and institutions, the 21 partners from the public partner list with their tier, and the 24 companies the organizer names as confirmed attendees on its homepage — 96 organizations in one list. Speakers appear as job titles, never by name, and nothing about an individual attendee is shown. The organizers publish no booth numbers.
How are organizations typed?
By the role an organization plays in degrader and induced proximity drug development: drug developers (large pharma and biotech), then the companies around them — CROs and CDMOs, tool, assay and reagent suppliers, software and AI companies, and investors and other services — and academic, government and non-profit bodies. The topic filters come from the track a session sits in and from what each session and partner covers.
How current is it?
Pulled from the public speaker faculty, the day-by-day agenda, the partner list and the homepage’s attendee banner on October 20, 2026, six days before the meeting opens. The organizers add and move sessions up to the meeting itself.
Browse TPD Summit 2026 by
Organizations with their own page
43 organizations — every exhibitor and every organization with 2 or more presentations.
- Ajinomoto Bio-Pharma Services
- Albert Einstein College of Medicine
- Amgen
- AntBio
- Aragen Life Sciences
- Arvinas
- Astellas
- AstraZeneca
- Biodesix
- BioIVT
- Broad Institute
- C4 Therapeutics
- Concarlo Therapeutics
- Degrome Therapeutics
- Edelris
- EditCo Bio
- Eli Lilly
- Enamine
- Evotec
- Foghorn Therapeutics
- Genentech
- Georgia Institute of Technology
- HitChem
- ICE Bioscience
- Janus Drug Discovery Consulting
- Larkspur Bioscience
- Monte Rosa Therapeutics
- NanoTemper Technologies
- NEOsphere Biotechnologies
- Novartis
- Nurix Therapeutics
- Pallando Therapeutics
- Pelago Bioscience
- Pin Therapeutics
- Promega
- Protai
- SAI Life Sciences
- Stablix
- Syngene International
- TGR BioSciences
- TrueCourse Biosciences
- UC Irvine
- Yale University
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction